Willem Joost Lesterhuis (W Joost Lesterhuis)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

Nature reviews. Cancer

Cancer immunology, immunotherapy : CII

Oncoimmunology

Nature protocols

Telethon Kids Institute

Radboud University Nijmegen (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Telethon Kids Institute Sep 01 2018

Australia

Head Sarcoma Group :: Cancer Centre

University of Western Australia Sep 17 2013

Australia

Research Fellow :: School of Biomedical Sciences

University of Amsterdam, Academic Medical Centre Sep 01 2012 - Sep 16 2013

Netherlands

Staff Medical Oncologist :: Department of Medical Oncology

University of Western Australia Dec 16 2010 - Aug 01 2012

Australia

Visiting post-doc :: Tumour Immunology

Education History

Radboud University Nijmegen Jan 01 2003 - Dec 06 2010

Netherlands

PHD :: Tumour Immunology

Publications

Rachael M Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V Long, Willem Joost Lesterhuis
Exploiting temporal aspects of cancer immunotherapy. Nature reviews. Cancer (2024)
Rachael M Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V Long, Willem Joost Lesterhuis
Exploiting temporal aspects of cancer immunotherapy. Nature reviews. Cancer 24 (7) (2024)
Rachael M Zemek, Wee Loong Chin, Vanessa S Fear, Ben Wylie, Thomas H Casey, Cath Forbes, Caitlin M Tilsed, Louis Boon, Belinda B Guo, Anthony Bosco, Alistair R R Forrest, Michael J Millward, Anna K Nowak, Richard A Lake, Timo Lassmann, Willem Joost Lesterhuis
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice. Nature communications 13 (1) (2022)
Jeroen H A Creemers, Willem Joost Lesterhuis, Niven Mehra, Winald R Gerritsen, Carl G Figdor, Ingrid Jolanda M De Vries, Johannes C Textor
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal for immunotherapy of cancer 9 (5) (2022)
Rachael M Zemek, Vanessa S Fear, Cath Forbes, Emma de Jong, Thomas H Casey, Louis Boon, Timo Lassmann, Anthony Bosco, Michael J Millward, Anna K Nowak, Richard A Lake, Willem Joost Lesterhuis
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nature protocols 15 (5) (2020)
Steve Boudewijns, Martine Bloemendal, Nienke de Haas, Harm Westdorp, Kalijn Fredrike Bol, Ghaith Bakdash, Erik H J G Aarntzen, Willem Joost Lesterhuis, Mark A J Gorris, Alexandra Croockewit, Lieke L van der Woude, Michelle M van Rossum, Marieke Welzen, Anna de Goede, Stanleyson V Hato, Winette T A van der Graaf, Cornelis J A Punt, Rutger H T Koornstra, Winald R Gerritsen, Carl G Figdor, Ingrid Jolanda M De Vries
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer immunology, immunotherapy : CII 69 (3) (2020)
Rachael M Zemek, Emma De Jong, Wee Loong Chin, Iona S Schuster, Vanessa S Fear, Thomas H Casey, Cath Forbes, Sarah J Dart, Connull Leslie, Ayham Zaitouny, Michael Small, Louis Boon, Alistair R R Forrest, Daithi O Muiri, Mariapia A Degli-Esposti, Michael J Millward, Anna K Nowak, Timo Lassmann, Anthony Bosco, Richard A Lake, Willem Joost Lesterhuis
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science translational medicine 11 (501) (2020)
Wayne J Aston, Danika E Hope, Alistair M Cook, Louis Boon, Ian M Dick, Anna K Nowak, Richard A Lake, Willem Joost Lesterhuis
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology 8 (11) (2019)

Willem Joost Lesterhuis.css-eqlu8i{font-size:small;padding-left:4px;} (W Joost Lesterhuis)

Publication Activity (10 Years)

Top Topics

Top Venues

Willem Joost Lesterhuis (W Joost Lesterhuis)